

Ulrich A Walker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6789952/publications.pdf>

Version: 2024-02-01

85
papers

9,118
citations

172457

29
h-index

58581

82
g-index

86
all docs

86
docs citations

86
times ranked

8865
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
2	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.9	1,705
3	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1809-1815.	0.9	1,017
4	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.9	794
5	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.9	410
6	Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility. <i>Arthritis Research and Therapy</i> , 2014, 16, R122.	3.5	290
7	Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. <i>Aids</i> , 2002, 16, 2165-2173.	2.2	185
8	Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2087-2093.	0.9	168
9	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. <i>PLoS ONE</i> , 2016, 11, e0163894.	2.5	158
10	Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. <i>Journal of Pathology</i> , 2005, 207, 436-444.	4.5	136
11	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.9	132
12	Digital ulcers predict a worse disease course in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 681-686.	0.9	111
13	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 103-109.	0.9	93
14	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.9	82
15	Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern". <i>Autoimmunity Reviews</i> , 2019, 18, 102394.	5.8	79
16	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. <i>Arthritis Research and Therapy</i> , 2018, 20, 17.	3.5	75
17	Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 1579-1585.	1.9	63
18	Functional disability and its predictors in systemic sclerosis: a study from the DeSSciper project within the EUSTAR group. <i>Rheumatology</i> , 2018, 57, 441-450.	1.9	60

#	ARTICLE	IF	CITATIONS
19	Imaging tools for the clinical assessment of idiopathic inflammatory myositis. <i>Current Opinion in Rheumatology</i> , 2008, 20, 656-661.	4.3	58
20	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1285-1292.	0.9	56
21	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	5.0	52
22	Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study. <i>Rheumatology</i> , 2017, 56, 1484-1491.	1.9	52
23	Role of MRI in Diagnosis and Management of Idiopathic Inflammatory Myopathies. <i>Current Rheumatology Reports</i> , 2015, 17, 67.	4.7	51
24	Brief Report: Severe Inflammation Following Vaccination Against <i>Streptococcus pneumoniae</i> in Patients With Cryopyrin-Associated Periodic Syndromes. <i>Arthritis and Rheumatology</i> , 2016, 68, 516-520.	5.6	42
25	Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group. <i>Arthritis Research and Therapy</i> , 2012, 14, R37.	3.5	41
26	Impaired skeletal muscle microcirculation in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R209.	3.5	38
27	Time-dependent and somatically acquired mitochondrial DNA mutagenesis and respiratory chain dysfunction in a scleroderma model of lung fibrosis. <i>Scientific Reports</i> , 2014, 4, 5336.	3.3	35
28	Effects of Didanosine-Related Depletion of mtDNA in Human T Lymphocytes. <i>Journal of Infectious Diseases</i> , 2005, 191, 848-855.	4.0	34
29	Mitochondrial DNA mutations and respiratory chain dysfunction in idiopathic and connective tissue disease-related lung fibrosis. <i>Scientific Reports</i> , 2019, 9, 5500.	3.3	32
30	Haematopoietic stem cell transplantation in systemic sclerosis. <i>RMD Open</i> , 2018, 4, e000533.	3.8	31
31	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1576-1582.	0.9	31
32	Streptococcal hypersensitivity reloaded: severe inflammatory syndrome in Behçet's disease following 23-valent polysaccharide <i>Streptococcus pneumoniae</i> vaccine. <i>Rheumatology</i> , 2012, 51, 761-762.	1.9	29
33	Pharmacological treatment options for cryopyrin-associated periodic syndromes. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 855-864.	3.1	29
34	Disease activity dynamics in rheumatoid arthritis: patients' self-assessment of disease activity via WebApp. <i>Rheumatology</i> , 2017, 56, 1707-1712.	1.9	29
35	Mild Course of COVID-19 and Spontaneous Virus Clearance in a Patient With Depleted Peripheral Blood B Cells Due to Rituximab Treatment. <i>Arthritis and Rheumatology</i> , 2020, 72, 1581-1582.	5.6	28
36	Muscle involvement in systemic sclerosis: points to consider in clinical trials. <i>Rheumatology</i> , 2017, 56, v38-v44.	1.9	27

#	ARTICLE	IF	CITATIONS
37	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. <i>Rheumatology</i> , 2020, 59, 1684-1694.	1.9	27
38	Trial of Tocilizumab in Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2017, 377, 1493-1495.	27.0	26
39	Mitochondrial toxicity in HIV type-1-exposed pregnancies in the era of highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2009, 14, 331-338.	1.0	26
40	Prematurely aging mitochondrial DNA mutator mice display subchondral osteopenia and chondrocyte hypertrophy without further osteoarthritis features. <i>Scientific Reports</i> , 2020, 10, 1296.	3.3	22
41	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101707.	3.3	22
42	An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S47-54.	0.8	21
43	Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 230-236.	1.9	20
44	Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases—a prospective multi-centre cohort study. <i>Rheumatology</i> , 2019, 58, 1585-1596.	1.9	19
45	Natural variability in the disease course of SSc-ILD: implications for treatment. <i>European Respiratory Review</i> , 2021, 30, 200340.	7.1	18
46	Personalized prediction of disease activity in patients with rheumatoid arthritis using an adaptive deep neural network. <i>PLoS ONE</i> , 2021, 16, e0252289.	2.5	18
47	Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1680.2-1685.	0.9	16
48	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. <i>Arthritis and Rheumatology</i> , 2018, 70, 1829-1834.	5.6	15
49	Impact of assessing patient-reported outcomes with mobile apps on patient-provider interaction. <i>RMD Open</i> , 2021, 7, e001566.	3.8	14
50	Assessment of cutaneous microcirculation in unaffected skin regions by transcutaneous oxygen saturation monitoring and Laser Doppler flowmetry in systemic sclerosis. <i>Clinical Hemorheology and Microcirculation</i> , 2015, 60, 263-271.	1.7	13
51	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1681-1685.	0.9	13
52	Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S75-9.	0.8	13
53	Erectile Dysfunction in Systemic Sclerosis. <i>Current Rheumatology Reports</i> , 2016, 18, 49.	4.7	12
54	Pyoderma Gangrenosum and Erythema Nodosum Revealing Takayasu's Arteritis. <i>Case Reports in Dermatology</i> , 2017, 8, 354-357.	0.8	12

#	ARTICLE	IF	CITATIONS
55	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 626-628.	0.9	12
56	Quantitative dynamic contrast-enhanced ultrasound for the functional evaluation of the skeletal muscle microcirculation in systemic sclerosis. <i>Clinical Hemorheology and Microcirculation</i> , 2016, 62, 35-44.	1.7	12
57	Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 139.	2.7	11
58	A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. <i>BMJ Open</i> , 2021, 11, e044483.	1.9	11
59	Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the I ² -Confident Registry. <i>RMD Open</i> , 2021, 7, e001663.	3.8	11
60	Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2019, 21, 76.	3.5	10
61	Patient and healthcare professional eHealth literacy and needs for systemic sclerosis support: a mixed methods study. <i>RMD Open</i> , 2021, 7, e001783.	3.8	9
62	Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysis. <i>Rheumatology</i> , 2014, 53, 639-643.	1.9	8
63	Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors. <i>Rheumatology</i> , 2021, 61, 131-138.	1.9	8
64	Circulating mitochondrial DNA copy numbers represent a sensitive marker for diagnosis and monitoring of disease activity in systemic lupus erythematosus. <i>RMD Open</i> , 2021, 7, e002010.	3.8	8
65	Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion. <i>Rheumatology</i> , 2011, 50, 243-244.	1.9	7
66	Zidovudine Induces Visceral Mitochondrial Toxicity and Intra-Abdominal Fat Gain in a Rodent Model of Lipodystrophy. <i>Antiviral Therapy</i> , 2014, 19, 783-792.	1.0	7
67	Points to consider when doing a trial primarily involving the heart. <i>Rheumatology</i> , 2017, 56, v12-v16.	1.9	6
68	Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. <i>Rheumatology</i> , 2022, 61, 4035-4046.	1.9	6
69	Do Patients With Skin Psoriasis Show Subclinical Axial Inflammation on Magnetic Resonance Imaging of the Sacroiliac Joints and Entire Spine?. <i>Arthritis Care and Research</i> , 2019, 71, 1109-1118.	3.4	5
70	Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database. <i>Rheumatology</i> , 2022, 61, 743-755.	1.9	5
71	The burden of systemic sclerosis in Switzerland – the Swiss systemic sclerosis EUSTAR cohort. <i>Swiss Medical Weekly</i> , 2021, 151, w20528.	1.6	5
72	Prospective evaluation of the capillaroscopic skin ulcer risk index in systemic sclerosis patients in clinical practice: a longitudinal, multicentre study. <i>Arthritis Research and Therapy</i> , 2018, 20, 239.	3.5	4

#	ARTICLE	IF	CITATIONS
73	Influence of Disease Activity in Rheumatoid Arthritis on Radiographic Progression of Concomitant Interphalangeal Joint Osteoarthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 43-49.	5.6	4
74	Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1203-1218.	3.1	4
75	Gout Arthritis During Admission for Decompensated Heart Failure—A Descriptive Analysis of Risk Factors, Treatment and Prognosis. <i>Frontiers in Medicine</i> , 2022, 9, 789414.	2.6	4
76	Effect of endothelin-1 receptor antagonists on skin fibrosis in scleroderma patients from the EUSTAR database. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 220-225.	1.7	3
77	Immunomodulation of rheumatologic disorders with non-biologic disease modifying antirheumatic drugs. <i>Seminars in Hematology</i> , 2016, 53, S58-S60.	3.4	3
78	Lumbar Radiculitis as a Complication of Vaccination against Tick-Borne Encephalitis: A Differential Diagnosis of Low Back Pain and Nerve Root Compression. <i>Case Reports in Medicine</i> , 2020, 2020, 1-4.	0.7	3
79	Circulatory Neutrophils Exhibit Enhanced Neutrophil Extracellular Trap Formation in Early Puerperium: NETs at the Nexus of Thrombosis and Immunity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13646.	4.1	3
80	Flare of a Cryopyrin-associated Periodic Syndrome Following Vaccination with Neisseria Meningitidis Polysaccharides. <i>Journal of Rheumatology</i> , 2018, 45, 878-879.	2.0	2
81	OP0105—HPR DO MOBILE APPS IMPROVE SHARED DECISION MAKING AND DISEASE MANAGEMENT IN THE RHEUMATIC DISEASES? AN EVALUATION OF APPS IN A SWISS RHEUMATOLOGY REGISTRY. , 2019, , .		2
82	A rare disease patient-reported outcome measure: revision and validation of the German version of the Systemic Sclerosis Quality of Life Questionnaire (SScQoL) using the Rasch model. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 356.	2.7	2
83	Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to controls: A multi-centre, observational study. <i>Travel Medicine and Infectious Disease</i> , 2020, 38, 101818.	3.0	1
84	Lipoatrophy and Other Manifestations of Antiretroviral Therapeutics. , 0, , 273-290.		1
85	Making the Diagnosis of Myositis: Muscle MRI. , 2020, , 145-160.		0